Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
GlobalData on MSN6d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
argenx SE (NASDAQ:ARGX) Shares Purchased by Envestnet Portfolio Solutions Inc.
Envestnet Portfolio Solutions Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 1,509 shares of the ...
Investor's Business Daily on MSN6d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Medical Dialogues6d
JnJ Nipocalimab gets USFDA Fast Track designation for Sjogren's disease
House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...
Pharmabiz6d
US FDA grants Fast Track designation to Johnson & Johnson’s nipocalimab to treat adult patients with moderate-to-severe Sjögren’s disease
Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...
Managed Healthcare Executive4d
FDA Approves Tremyfa to Treat Active Crohn’s Disease
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Monthly Prescribing Reference5d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
Vutrisiran is a transthyretin-directed small interfering RNA therapeutic that was previously approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Managed Healthcare Executive4d
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...